

Selexis To Be Acquired by JSR Life Sciences

Torreya Advised Selexis on Sale

Tokyo, Japan and Geneva, Switzerland, June 14, 2017

Selexis SA, a global leader in mammalian cell-line generation technologies, announced today it has agreed to be acquired by JSR Life Sciences, the life sciences division of JSR Corporation.

Selexis' operations will be merged with those of JSR's KBI Biopharma, creating the most robust and quickest "Gene to GMP" service offering in the biopharmaceutical industry. Selexis' best-in-class cell-line development technology, combined with KBI Biopharma's analytical, development and manufacturing expertise, will give patients access to critical drugs sooner and will accelerate the development of future life-saving medicines.

Torreya served as advisor to Selexis on this transaction, which reinforces Torreya's strength and leadership position as an advisor to pharmaceutical services companies.

ABOUT JSR LIFE SCIENCES DIVISION

For more information about JSR Life Sciences, please see: www.jsrlifesciences.com.

ABOUT SELEXIS SA

For more information about Selexis SA, please see: www.selexis.com.

ABOUT KBI BIOPHARMA

For more information about KBI Biopharma, please see: www.kbibipharma.com.

Deal Press Release

Torreya Contact

TOM BIRD

Partner & Co-Head of North American Transactions | New York Office

tom.bird@torreya.com | 212.257.5806 | torreya.com

SELEXIS[®]

Sale of company to



JSR Life Sciences

June 2017

Torreya is a global advisory firm serving the life sciences industry. Please visit www.torreya.com for more information. Securities offered in the United States are offered through Financial West Group, Member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 119 The Hub, 300 Kensal Road, London W10 5BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.